Audio roundup of selected biopharma industry content from Scrip over the business week ended June 12, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.<br><br>This time–Lilly explores Zepbound in autoimmune disorders; AstraZeneca pursues interconnected strategy in CVRM; AstraZeneca moving oral GLP-1 into Phase III; Boehringer pursues quality weight loss with survodutide; and GSK scales oncology ambitions with Nuvalent buy.<br><br>Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-LLJSGYAJJ5EO3J5JMQYNNNSCMU/

Scrip's Five Must-Know Things - Jun. 15, 2026 

Citeline Podcasts

Hello and welcome to the podcast edition of Scrip's's Five Must-Know Things, this time for the Business Week ended June 12, 2026. This is Ian Hadock. This episode was produced with the help of AI-powered text to voice and voice emulation tools. This time, Lily explores Zetbound in autoimmune disorders. AstraZeneca pursues interconnected strategy in CVRM.

AstraZeneca moving oral GLP-1 into Phase 3. Boehringer pursues quality weight loss with cervidutide. And GSK scales oncology ambitions with Nuvalent Bi. Lilly looks set to expand the success of its blockbuster T-Zipatide after a pair of Phase 3 study wins in psoriatic arthritis and psoriasis, Andrew McConaughey writes.

Already the world's biggest selling drug thanks to its use in type 2 diabetes as Mounjaro and obesity as Zetbound, and with a sleep apnea approval added in 2024, Lily has now achieved success in two Phase 3 trials, together PSA and together PSO.

These saw the GLP-1 slash GIP receptor agonist help overweight and obese patients with psoriatic arthritis or psoriasis respectively when taken alongside its anti-IL-17A therapy TOLTS. Full results from together PSA were presented on June 3 at the European Alliance of Associations for Rheumatology conference in London, and Lily is now preparing to talk to regulators about both trials.

Together, PSA met its primary endpoint of a 50% improvement in PSA activity based on ACR50, in addition to greater than or equal to 10% weight reduction with concomitant TOLTS and Zetbound therapy at 36 weeks compared with TOLTS monotherapy. If approved, this expansion into autoimmune diseases would help boost Lily's presence in immunology and give it an advantage over rival Novo Nordisk,

Scrip's Five Must-Know Things - Jun. 15, 2026

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Scrip's Five Must-Know Things - Jun. 15, 2026

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.